According to filings with the U.S. Securities and Exchange Commission, Valid is raising up to $6,861,790.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Valid
The traditional drug development pipeline is marred by high failure rates and inefficiencies, largely due to unreliable and non-translating research models. VALID focuses on addressing this critical issue using advanced/complex hiPSC-derived models with increased predictive validity. Transforming Drug Development with VALID Techbio 2.0: Predictive Validity/Efficacy at Scale Better Data = Better Targets = Successful Drug Discovery.

To learn more about Valid, visit http://www.validtx.com/
Valid Linkedin Page: https://www.linkedin.com/company/valid-tx/

Contact:
Tim Ahfeldt, Chief Executive Officer
917-674-3889
https://www.linkedin.com/in/tim-ahfeldt-983a128b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.